Loading…
← CockpitCompetitor Analysis › LTGO Latigo Biotherapeutics, Inc.Open in the cockpit ↗

Latigo Biotherapeutics, Inc.LTGOCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Clinical-stage biotech developing a non-opioid Nav1.8 sodium-channel blocker for acute and chronic pain.

Mkt cap
$882M
US dollars, full cap
Free float
44%
of shares outstanding
$/day
$4.14M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 8.9%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$13.31
1D-3.3%
1W-1.6%
1M-12.7%
3M-37.8%
6Mn/a
YTDn/a
1Yn/a
ATR %11.5%
52w lowhigh48.7% off high

What Latigo Biotherapeutics does

Clinical-stage biotech developing a non-opioid Nav1.8 sodium-channel blocker for acute and chronic pain.

Has no product on sale and earns nothing from customers, so trials are funded by money raised from investors. Its value rests on late-stage results for one drug class, and any later income would come from selling or licensing the drug.

Products and services

  • Nav1.8 blocker (acute/chronic pain)

Where it sits in the supply chain

  • Biopharma R&D
  • Sodium-channel (Nav1.8) pain drug…
  • Non-opioid analgesic clinical trials

What could go right

  • Non-opioid pain drug demand amid opioid crisis
  • Positive pivotal trial data

What could go wrong

  • First-mover advantage already held by Vertex
  • Binary late-stage trial risk

Moat: none (IP / patents). Pre-commercial; competes against Vertex's already-approved Nav1.8 drug Journavx in the same class.

Headquarters: South San Francisco, California, US · Founded: 2024

Named competitors

Latigo Biotherapeutics at a glance

Size Latigo Biotherapeutics (LTGO) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $882M, the 2304th largest of 3,085 United States companies the cockpit tracks. Shares closed at $13.31 on 18 Nov 2026.

Short interest Short interest is 1.4% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Latigo Biotherapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenuen/a$0$0
Revenue growth———
Gross profitn/a-$249,000-$244,000
EBITDAn/a-$110M-$63.2M
Net incomen/a-$109M-$61.2M
Free cash flown/a-$97.7M-$51.0M
Capital expendituren/a$136,000$72,000
Total debt$1.19M$690,000$851,000

Quarterly statements and history in the cockpit →

Latigo Biotherapeutics competitors and peer comparison

Head to head with its named competitors (LTGO vs VRTX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Latigo Biotherapeutics LTGO$882Mn/an/an/an/an/a
Vertex Pharmaceuticals VRTX$136B+25%+11%35%10.5×6.2%

How Latigo Biotherapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Latigo Biotherapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureLTGOPeer medianRank in peer set
1-month return-12.7%-9.3%9th lowest of 21
Distance from 52-week high-48.7%-44.1%10th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%0.9×-7.6%-0.7%
Aktis Oncology AKTSUnited States$895M-15%+337%-837%33.4×n/an/a
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%8.3×17.7%+22.7%
Pharming PHARM.ASNetherlands$867M-6%+2%9%2.2×2.4%+12.4%
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%0.8×n/an/a
GuangYuYuan Chinese Herbal Medicine 600771.SSChina$866M-26%-6%5%4.1×31.7%+4.2%
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%3.5×19.4%-6.0%
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%0.9×n/an/a
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%1.2×n/an/a
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%1.2×-4.2%+10.6%
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%55.9×n/an/a
Jiangsu Yahong Meditech 688176.SSChina$854M-20%+15%-172%15.3×n/an/a
Immatics IMTXUnited States$913M-46%-44%-589%8.5×n/an/a
Beijing Sun-Novo Pharmaceutical Research 688621.SSChina$849M-8%-1%-2%5.8×n/an/a
MoonLake Immunotherapeutics MLTXUnited States$918M-37%n/an/an/an/an/a
Lotus Pharmaceutical 1795.TWTaiwan$921M-37%+67%21%2.6×-3.7%+13.8%
Zhejiang Garden Biopharmaceutical 300401.SZChina$922M-14%+2%24%5.2×9.1%+13.4%
Oscotec 039200.KSSouth Korea$923M-32%+510%59%7.5×-10.2%+18.1%

Questions

Who are Latigo Biotherapeutics's main competitors?
Named competitors: Vertex Pharmaceuticals (VRTX). The cockpit's measured peer set (industry) also includes Northeast Pharmaceutical (000597.SZ), Aktis Oncology (AKTS), Sanofi Consumer Healthcare India (SANOFICONR.NS), Pharming (PHARM.AS), SK Discovery (006120.KS), GuangYuYuan Chinese Herbal Medicine (600771.SS).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.